Literature DB >> 17060686

Paracrine VEGF/VE-cadherin action on ovarian cancer permeability.

Limin Hu1, Napoleone Ferrara, Robert B Jaffe.   

Abstract

Ascites formation associated with neoplasms is most likely due to increased vascular permeability, a process in which vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) plays a pivotal role. We hypothesized that tumor-derived VEGF/VPF modulates ascites formation through a paracrine effect on both tumor and peritoneal vessels. We investigated human vascular endothelial permeability using a newly developed dual-chamber permeability assay by co-culturing human umbilical vein cells with and without ovarian cancer cell lines (OVCAR-3, Hey-A8, and OCC-1) in the presence or absence of a human VEGF monoclonal antibody and VE-cadherin function-blocking antibody. This method permits determination of mechanisms by which substances released from neoplasms and other sources of vascular endothelial cell secretagogues modulate vascular permeability and likely other pathologic states.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060686     DOI: 10.1177/153537020623101010

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  3 in total

1.  Mechanisms of tumor cell extravasation in an in vitro microvascular network platform.

Authors:  Michelle B Chen; Jordan A Whisler; Jessie S Jeon; Roger D Kamm
Journal:  Integr Biol (Camb)       Date:  2013-10       Impact factor: 2.192

2.  ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.

Authors:  James Greenaway; Jack Henkin; Jack Lawler; Roger Moorehead; Jim Petrik
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

3.  Differential roles of uPAR in peritoneal ovarian carcinomatosis.

Authors:  Nada N Al-Hassan; Ali Behzadian; Ruth Caldwell; Vessela S Ivanova; Viqar Syed; Kouros Motamed; Neveen A Said
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.